Comparison of Anticoagulation Prolongation vs. no Anticoagulation in STEMI Patients After Primary PCI
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2989 participants.
Also called NCT03664180
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 2,989 participants
- Sponsor
- Registry
-
NCT03664180
-
- Other papers using this trial's data
- Postprocedural Anticoagulation After Primary Percutaneous Coronary Intervention for ST-Segment-Elevation Myocardial Infarction: A Multicenter, Randomized, Double-Blind Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT03664180. Randomized; triple masking; primary purpose treatment. Start 2019-01-11 (actual); primary completion 2022-11-23 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Comparison of Anticoagulation Prolongation vs. no Anticoagulation in STEMI Patients After Primary PCI
- Acronym
- RIGHT
- Condition
- STEMI - ST Elevation Myocardial Infarction
- Intervention (Drug)
- Bivalirudin
- Intervention (Drug)
- Enoxaparin
- Intervention (Drug)
- Unfractionated heparin
- Intervention (Drug)
- Bivalirudin placebo
- Intervention (Drug)
- Enoxaparin placebo syringe
- Intervention (Drug)
- Unfractionated heparin placebo
- Lead sponsor
- Beijing Anzhen Hospital
- Collaborator
- Chinese Academy of Medical Sciences, Fuwai Hospital
- Collaborator
- Groupe Hospitalier Pitie-Salpetriere
Record details
- Record id
cardio:ct-nct03664180- Content hash
2d95261b8b9a92df962b79bb30ac587dc471768d83edd039bef3313a1649e373